Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Menzel, H; Müller, A; Von Schilling, C; Licht, T; Peschel, C; Keller, U 
Titel:
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization. 
Abstract:
Chemotherapy with ifosfamide, epirubicin and etoposide (IEV) is an effective treatment regimen for refractory/relapsed non-Hodgkin lymphoma (NHL). Rituximab has been shown to improve response rates, progression-free survival and overall survival in B-cell NHL. This study included 85 patients who were treated with IEV or rituximab-IEV (R-IEV) for refractory/relapsed B-cell NHL. The overall response rate was 40.7% (IEV) versus 68.8% (R-IEV). Fever occurred after 23.4% of IEV and 19.4% of R-IEV cyc...    »
 
Zeitschriftentitel:
Leuk Lymphoma 
Jahr:
2008 
Band / Volume:
49 
Heft / Issue:
Seitenangaben Beitrag:
1337-44 
Sprache:
eng 
Print-ISSN:
1042-8194 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik